Xoma (XOM) Q3 2026 earnings summary

Executive summary

• Q3 focus remained on advancing FLOW toward industrial use while strengthening financial flexibility; operations remained loss-making.

• Q3 operating revenue was SEK 1.615m, including a SEK 1m Nordnet settlement; Q3 net loss was SEK 1.630m.

Financial highlights

• Q3 operating revenue rose to SEK 1.615m from SEK 0.325m YoY; 9M revenue was SEK 2.806m vs SEK 0.672m.

• Q3 EBITDA was -SEK 1.618m vs -SEK 2.295m; EBIT was -SEK 1.630m vs -SEK 2.329m.

• 9M EBITDA was -SEK 6.633m vs -SEK 5.763m; EBIT was -SEK 6.873m vs -SEK 5.857m.

• 9M net loss was SEK 6.875m vs SEK 5.860m; EPS was -SEK 0.06 vs -SEK 0.09.

• Revenue included capitalized FLOW development costs and a SEK 1m settlement; 9M operating cash flow after working capital was -SEK 7.590m.

Outlook and guidance

• Pilot work with Boliden Rönnskär continues; management plans to provide a clearer timeline.

• Algonova Bio's biogenic silica project is underway, with an updated timeline for its listing process to follow.

• Management aims to expand domestic and international partnerships while verifying and scaling FLOW technology.